Beta Alanine

Study: Meta-analysis of 15 randomized, double-blind, placebo-controlled trials involving human participants. Studies used chronic beta-alanine supplementation (4–6 g/day) for 2–12 weeks, assessing exercise capacity and performance (e.g., time to exhaustion, power output) in activities lasting 60 seconds to over 240 seconds.

Findings: Beta-alanine significantly improved exercise capacity, especially for high-intensity exercises lasting 1–4 minutes (effect size 0.18). Time to exhaustion increased by 13–19% in open-ended tasks. Benefits were less consistent for fixed endpoint tasks or exercises under 60 seconds or over 240 seconds. Two studies showed enhanced peak power in 30-second sprints post-cycling.

Study: Systematic review and meta-analysis of 101 human and 50 animal studies, evaluating side effects, biomarkers, and muscle taurine/histidine levels. Human studies were double-blind, placebo-controlled, using 4–6 g/day beta-alanine for weeks to months. Quality was assessed via the GRADE framework.

Findings: Paresthesia (tingling) was the only consistent side effect (odds ratio 8.9 vs. placebo), deemed non-harmful. No significant changes in muscle taurine or histidine were found. A small increase in alanine aminotransferase (ALT) occurred (effect size 0.274), but within clinical norms. Dropout rates were similar to placebo, indicating good tolerability.

Study: Systematic review of 18 randomized, double-blind, placebo-controlled trials with 331 trained males (18–40 years). Beta-alanine doses were 3.2–6.4 g/day for 2–12 weeks, focusing on maximal/supramaximal exercises (0.5–10 minutes) like cycling, rowing, and sprinting.

Findings: Significant improvements in exercise performance, particularly for 1–4 minute durations, with enhanced time to exhaustion and work capacity. No consistent strength gains were observed. Paresthesia was reported in some participants but was manageable.

Study: Randomized, double-blind, placebo-controlled trial with 16 participants (8 per group) receiving 5 g/day beta-alanine or placebo for 23 days. Performance was measured via a 10-km running time trial, with post-exercise lactate levels assessed. Participants trained 7–12 km with sprints three times weekly.

Findings: Beta-alanine reduced 10-km running time (3441 ± 326.7 s to 3209 ± 270.5 s, p < 0.05) and lowered post-exercise lactate, suggesting enhanced buffering capacity improved aerobic performance.

Study: Thirty strength-trained participants were randomized to 6.4 g/day beta-alanine (8 × 800 mg) or placebo during a 5-week resistance training program (3 sessions/week, leg exercises). Outcomes included power output, one-repetition maximum (1RM), and training volume.

Findings: Beta-alanine increased power output at 1RM, kilograms lifted, maximum power, number of sets, and pre-post gains in incremental load tests, attributed to enhanced muscle buffering and workload capacity.

Study: Randomized, double-blind, placebo-controlled trial with 19 men (10 beta-alanine, 9 placebo) receiving 15 g/day sustained-release beta-alanine (BETAFOR3MAX®) or placebo for 30 days. Blood parameters (triglycerides, LDL-cholesterol, urea nitrogen) and paresthesia were measured.

Findings: Beta-alanine increased triglycerides, LDL-cholesterol, and urea nitrogen vs. baseline, but not vs. placebo. Paresthesia was reported but not significantly worse than placebo, suggesting sustained-release formulations improve tolerability at high doses.